March 17, 2016

The Honorable Mitch McConnell Majority Leader U.S. Senate Washington, D.C. 20510

The Honorable Harry Reid Minority Leader U.S. Senate Washington, D.C. 20510 The Honorable Paul Ryan Speaker of the House of Representatives U.S. House of Representatives Washington, D.C. 20515

The Honorable Nancy Pelosi Minority Leader U.S. House of Representatives Washington, D.C. 20515

Dear Leader McConnell, Leader Reid, Speaker Ryan and Leader Pelosi:

We, the 316 organizations listed below, are writing to express our strong concern with the Centers for Medicare & Medicaid Services' (CMS) March 8, 2016 proposed rule that would implement a new "Medicare Part B Payment Model." We believe that this type of initiative, implemented without sufficient stakeholder input, will adversely affect the care and treatment of Medicare patients with complex conditions, such as cancer, macular degeneration, hypertension, rheumatoid arthritis, Crohn's disease and ulcerative colitis, and primary immunodeficiency diseases. We previously sent a letter to Department of Health and Human Services (HHS) Secretary Sylvia Burwell asking her not to move forward with this type of initiative, and we now respectfully request that you ask CMS to withdraw the proposed rule.

Medicare beneficiaries – representing some of the nation's oldest and sickest patients – must often try multiple prescription drugs and/or biologics before finding the appropriate treatment for their complex conditions. These patients need immediate access to the right medication, which is already complicated by the fact that treatment decisions may change on a frequent basis. These vulnerable Medicare patients and the providers who care for them already face significant complexities in their care and treatment options, and they should not face mandatory participation in an initiative that may force them to switch from their most appropriate treatment.

A Center for Medicare & Medicaid Innovation (CMMI) initiative that focuses on costs rather than patients and health care quality, implemented based on primary care service areas, rather than the unique challenges of patients, is misguided and ill-considered. Medicare beneficiaries with life-threatening and/or disabling conditions would be forced to navigate a CMS initiative that could potentially lead to an abrupt halt in their treatment. This is not the right way to manage the Medicare program for its beneficiaries.

As CMS contemplates payment and delivery system reforms, there is a critical need for transparent, comprehensive communications with stakeholders throughout the process. We were deeply disappointed that CMS only provided a limited opportunity for stakeholder input before announcing sweeping proposed changes to Medicare Part B drug payments. In doing so, the agency largely failed to consider stakeholder concerns that the initiative could adversely impact patients' access to life-saving and life-changing Medicare Part B covered drugs.

We believe these types of initiatives should be initially implemented in a targeted, patient-centered and transparent way that accounts for the unique needs of Medicare beneficiaries. In fact, CMMI is statutorily required to ensure that its initiatives target "deficits in care," and can only expand the

scope and duration of a model after careful assessment of the model's impact on quality of care, patient access, and spending. We are very deeply concerned, therefore, that CMS' proposed Part B Model would be applied on a nationwide basis – to all states except Maryland, due to its all-payer model – and would include the "majority" of Part B drugs. Furthermore, given the success of the current Part B reimbursement methodology in ensuring patient access to the most appropriate treatments, it is unclear what "deficits in care" CMS is attempting to address in this incredibly wide-ranging initiative.

In the proposed rule, CMS expresses concern that the 6% ASP add-on payment "may encourage the use of more expensive drugs because the 6 percent add-on generates more revenue for more expensive drugs." This assumption fails to take into account the fact that providers' prescribing decisions depend on a variety of factors, including clinical characteristics and the complex needs of the Medicare population. Most importantly, there is no evidence indicating that the payment changes contemplated by the model will improve quality of care, and may adversely impact those patients that lose access to their most appropriate treatments. In fact, data suggests that the current Part B drug payment system has been <u>both</u> cost effective and successful in ensuring patient access to their most appropriate treatment, as Part B expenditures remain relatively stable<sup>1</sup> and Part B drugs account for just 3% of total program costs.<sup>2</sup>

Finally, it is important to understand that with the Budget Control Act, CMS has already cut Medicare reimbursement for physician-administered drugs by 2%, further impacting some providers' ability to administer essential drugs <u>at the current reimbursement rate</u>. It is imperative CMS acknowledges and evaluates the impact of the current, real payment rate and engages multiple stakeholders, starting with patients and providers, <u>before implementing a new</u>, severe reimbursement <u>cut</u> that is effectively ASP + 0.86% (plus a small flat fee). In closing, we urge you to ensure that our nation's oldest and sickest patients continue to be able to access their most appropriate drugs and services. We therefore request that you ask CMS to permanently withdraw the Part B Drug Payment Model from consideration.

Sincerely,

1 in 9: The Long Island Breast Cancer Action Coalition Action CF ADAP Advocacy Association (aaa+) Advocates for Responsible Care (ARxC) Aimed Alliance Alabama Academy of Ophthalmology Alabama Cancer Congress Alabama Gastroenterological Society Alaska Society of Eye Physicians and Surgeons

<sup>&</sup>lt;sup>1</sup> 2015 Medicare Trustees Report.

<sup>&</sup>lt;sup>2</sup> Medicare Payment Advisory Commission, "Medicare Drug Spending;" presentation at September 2015 public meeting; available at: <u>http://www.medpac.gov/documents/september-2015-meeting-presentation-medicare-drug-spending.pdf?sfvrsn=0</u>.

Alliance for Patient Access (AfPA) Alliance of Specialty Medicine Alzheimer's and Dementia Alliance of Wisconsin American Academy of Allergy Asthma and Immunology (AAAAI) American Academy of Ophthalmology American Association of Diabetes Educators American Bechet's Disease Association American College of Mohs Surgery American College of Rheumatology American Gastroenterological Association American Liver Foundation, Upper Midwest Division American Society of Clinical Oncology (ASCO) American Urological Association AmerisourceBergen Anticoagulation Forum Arizona BioIndustry Association (AZBio) Arizona United Rheumatology Alliance Arkansas State Rheumatology Association Arthritis Foundation Asian Americans for Community Involvement Association of Black Cardiologists Association of Community Cancer Centers (ACCC) Association of Idaho Rheumatologists Association of Indian Physicians of Ohio Association of Northern California Oncologists (ANCO) Association of Women in Rheumatology (AWIR) Asthma & Allergy Foundation of America, New England Chapter Axis Advocacy Biocom BioFlorida. Inc. **BioForward BioHouston BioKansas BioNJ Bionorth TX** Bioscience Association of West Virginia Biotechnology Innovation Organization (FKA Biotechnology Industry Organization) **BioUtah** Brain Injury Association of Georgia California Academy of Eye Physicians and Surgeons California Hepatitis C Task Force California Life Sciences Association (CLSA)

California Rheumatology Alliance (CRA) Cancer Support Community Cancer Support Community Central Ohio Cancer Support Community North Texas CancerCare Cardinal Health Caregiver Action Network **Caring Ambassadors Cascade AIDS Project** Center for Healthcare Innovation Central Texas Rheumatology Society Chicago Life Sciences Consortium (CLSC) COA Patient Advocacy Network (CPAN) Coalition of Hematology Oncology Practices (CHOP) Coalition of State Rheumatology Organizations (CSRO) Coalition of Texans with Disabilities (CTD) Colon Cancer Alliance Colorado BioScience Association Colorado Gerontological Society Colorado Rheumatology Association Colorado Society of Eye Physicians and Surgeons (CSEPS) Colorado State Grange Community Access National Network (CANN) Community Liver Alliance Community Oncology Alliance (COA) Connecticut Oncology Association (CtOA) **Connecticut Rheumatology Association** Cutaneous Lymphoma Foundation Delaware Academy of Ophthalmology **Delaware BioScience Association** Dia de la Mujer Latina Digestive Disease National Coalition (DDNC) Digestive Health Physicians Association (DHPA) Easter Seals Massachusetts Eastern Pennsylvania Chapter, National Hemophilia Foundation **EDSers United Foundation** Elder Care Advocacy of Florida Epilepsy Foundation of Greater Chicago Epilepsy Foundation of Western Wisconsin Fabry Support and Information Group Florida Allergy, Asthma & Immunology Society (FAAIS) Florida Gastroenterologic Society

Florida Psychiatric Society Florida Society of Clinical Oncology (FLASCO) Florida Society of Neurology Florida Society of Ophthalmology Florida Society of Rheumatology Florida State Hispanic Chamber of Commerce **GBS**|CIDP Foundation International Georgia Bio Georgia Chapter of the American College of Cardiology Georgia Mental Health Consumer Network Georgia Society of Clinical Oncology (GASCO) Georgia Society of Rheumatology **Global Colon Cancer Association Global Healthy Living Foundation** H.E.A.L.S of the South Hawaii Society of Clinical Oncology Health Coalition, Inc. Healthcare Distribution Management Association Healthcare Institute of New Jersey (HINJ) Healthcare Leadership Council HealthHIV Hematology-Oncology Managers of New York (HOMNY) Hepatitis Foundation International iBio - Illinois Biotechnology Industry Organization Idaho Society of Clinical Oncology Idaho Society of Ophthalmology Illinois Medical Oncology Society Illinois Society of Eye Physicians & Surgeons (ISEPS) Immune Deficiency Foundation (IDF) Indiana Academy of Ophthalmology (IAO) Indiana Health Industry Forum (IHIF) Indiana Oncology Society **INDUNIV** Research Consortium International Cancer Advocacy Network (ICAN) International Foundation for Autoimmune Arthritis (IFAA) International Institute For Human Empowerment, Inc. **ION Solutions** Iowa Academy of Ophthalmology (IAO) Iowa Biotechnology Association Iowa Oncology Society Iowa State Grange Kansas City Area Life Sciences Institute, Inc.

Kansas Rheumatology Alliance Kansas Society of Clinical Oncology Kansas Society of Eye Physicians & Surgeons (KSEPS) Kentuckiana Rheumatology Alliance Kentucky Association of Medical Oncology (KAMO) Kentucky Life Sciences Council Large Urology Group Practice Association (LUGPA) Life Science Washington Louisiana Oncology Society Lung Cancer Alliance LUNGevity Lupus Foundation of America (LFA), Indiana Chapter Lupus Foundation of Colorado Maryland DC Society of Clinical Oncology Maryland Society for the Rheumatic Diseases (MSRD) Massachusetts Association for Mental Health Massachusetts Society of Eye Physicians and Surgeons (MSEPS) Massachusetts, Maine and New Hampshire Rheumatology Association MassBio Mayors Committee on Life Sciences McKesson Medical Oncology Association of Southern California (MOASC) Medical Partnership 4 MS Medical Society of the State of New York Men's Health Network Mental Health Systems, Inc. Metropolitan Atlanta Rheumatology Society (MARS) MichBio - Michigan Biosciences Industry Association Michigan Lupus Foundation Michigan Osteopathic Association Michigan Rheumatism Society Michigan Society of Eye Physicians and Surgeons (MiSEPS) Michigan Society of Hematology and Oncology (MSHO) Midwest Oncology Practice Society (MOPS) Minnesota Academy of Ophthalmology Minnesota Society of Clinical Oncology Mississippi Academy of Eye Physicians and Surgeons Mississippi Arthritis and Rheumatology Society Mississippi Oncology Society Missouri Biotechnology Association (MOBIO) Missouri Oncology Society Missouri Society of Eye Physicians & Surgeons (MoSEPS)

Montana BioScience Alliance Montana State Oncology Society NASW-NC (National Association of Social Workers) National Alliance on Mental Illness (NAMI) National Alliance on Mental Illness Greater Des Moines (NAMI) National Alliance on Mental Illness Iowa (NAMI) National Alliance on Mental Illness Kentucky (NAMI) National Alliance on Mental Illness Texas (NAMI) National Association for Rural Mental Health National Association of County Behavioral Health & Developmental Disability Directors (NACBHDD) National Association of Hepatitis Task Forces National Blood Clot Alliance (NBCA) National Cancer Care Alliance National Hispanic Medical Association National Infusion Center Association (NICA) National Medical Association (NMA) National Minority Quality Forum National MPS Society National Patient Advocate Foundation Nebraska Academy of Eye Physicians and Surgeons Nebraska Medical Association (NMA) Nebraska Oncology Society Neurofibromatosis Mid-Atlantic Nevada Oncology Society New England Biotech Association (NEBA) New Jersey Academy of Ophthalmology New Jersey Association of Mental Health and Addiction Agencies, Inc. (NJAMHAA) New Jersey Rheumatology Association New Jersey Society for Oncology Managers (NJSOM) New York State Ophthalmological Society New York State Rheumatology Society NewYorkBIO **NMBio** NORM - National Organization of Rheumatology Managers North American Thrombosis Forum North Carolina Biosciences Organization (NCBIO) North Carolina Oncology Association North Carolina Psychiatric Association North Carolina Psychological Association North Carolina Rheumatology Association (NCRA) North Carolina Society of Eye Physicians and Surgeons (NCSEPS)

Northern New England Clinical Oncology Society Ohio Association of Rheumatology Ohio Foot and Ankle Medical Association **Ohio Gastroenterology Society Ohio Hematology Oncology Society** Ohio Ophthalmological Society (OOS) Oklahoma Academy of Ophthalmology Oklahoma Society of Clinical Oncology **Oncology Managers of Florida Oncology Nursing Society Oregon Bioscience Association Oregon Rheumatology Alliance** Oregon Society of Medical Oncology (OSMO) **Oregon State Grange** Oregon Urological Society Patients Rising PCa Blue Inc. Pennsylvania Academy of Ophthalmology Pennsylvania Bio Pennsylvania Rheumatology Society Pennsylvania State Grange Pharmaceutical Research and Manufacturers of America (PhRMA) Philadelphia Rheumatism Society Phoenix Rheumatology Association Physicians Advocacy Institute (PAI) Premier Oncology Hematology Management Society (POHMS) **Prevent Blindness** Prevent Blindness, Ohio Affiliate Prevent Cancer Foundation Prostate Conditions Education Council (PCEC) Puerto Rico Society of Ophthalmology Pulmonary Hypertension Association Quality Cancer Care Alliance (QCCA) RetireSafe Rheumatism Society of the District of Columbia Rheumatology Alliance of Louisiana Rheumatology Association of Iowa (RAI) Rocky Mountain Oncology Society Rush To Live Salud USA **SCBIO** Society for Women's Health Research

Society of Utah Medical Oncologists South Carolina Gastroenterology Association South Carolina Oncology Society South Carolina Rheumatism Society South Carolina Society of Ophthalmology South Dakota Biotech South Florida Cancer Association Southern California Rheumatology Society (SCRS) Spina Bifida Association of Kentucky State of Texas Association of Rheumatologists (STAR) State of Texas Kidney Foundation StopAfib.org Taking Control Of Your Diabetes (TCOYD) Tech Council of Maryland Tennessee Oncology Practice Society (TOPS) Tennessee Rheumatology Society Texas Association of Business Texas Association of Manufacturers **Texas BioAlliance** Texas Healthcare and Bioscience Institute (THBI) **Texas Life Sciences Collaboration Center Texas Nurse Practitioners** Texas Ophthalmological Association Texas Society of Clinical Oncology **Texas State Grange** The American College of Surgeons/Commission on Cancer The Arizona Clinical Oncology Society The Crohn's Colitis Effect The Medical Alley Association The Mended Hearts, Inc. The Retina Society The US Oncology Network The Vasculitis Foundation U.S. Hereditary Angioedema Association United States Cutaneous Lymphoma Consortium Utah Ophthalmology Society Veterans Health Council Vietnam Veterans of America Virginia Association of Hematologists & Oncologists Virginia Biotechnology Association Virginia Hematology Oncology Association (VAHO) Virginia Society of Eye Physicians and Surgeons

Washington Academy of Eye Physicians and Surgeons Washington Rheumatology Alliance Washington State Medical Oncology Society Washington State Prostate Cancer Coalition Washington State Urology Society Wellness and Education Community Action Health Network West Virginia Oncology Society West Virginia Rheumatology State Society Wisconsin Academy of Ophthalmology Wisconsin Association of Hematology & Oncology Wisconsin Association of Osteopathic Physicians & Surgeons Wisconsin Rheumatology Association Wyoming Epilepsy Association Wyoming Ophthalmological Society

**cc:** The Honorable Orrin Hatch Chairman Committee on Finance U.S. Senate

The Honorable Ron Wyden Ranking Member Committee on Finance U.S. Senate

The Honorable Fred Upton Chairman Committee on Energy and Commerce U.S. House of Representatives

The Honorable Kevin Brady Chairman Committee on Ways and Means U.S. House of Representatives

The Honorable Frank Pallone Ranking Member Committee on Energy and Commerce U.S. House of Representatives

The Honorable Sander Levin Ranking Member Committee on Ways and Means U.S. House of Representatives